409 related articles for article (PubMed ID: 34058255)
1. Clinical Value of Upfront Cranial Radiation Therapy in Osimertinib-Treated Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer With Brain Metastases.
Yu F; Ni J; Zeng W; Zhou Y; Guo T; Zeng Y; Zhao Y; Li S; Li Y; Yang X; Zou L; Wang S; Liu Q; Li Y; Chu L; Chu X; Ye L; Yu W; Zhu Z
Int J Radiat Oncol Biol Phys; 2021 Nov; 111(3):804-815. PubMed ID: 34058255
[TBL] [Abstract][Full Text] [Related]
2. Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR-mutant nonsmall cell lung cancer with brain metastasis.
Zhao Y; Li S; Yang X; Chu L; Wang S; Tong T; Chu X; Yu F; Zeng Y; Guo T; Zhou Y; Zou L; Li Y; Ni J; Zhu Z
Int J Cancer; 2022 Apr; 150(8):1318-1328. PubMed ID: 34914096
[TBL] [Abstract][Full Text] [Related]
3. Osimertinib for
Xie L; Nagpal S; Wakelee HA; Li G; Soltys SG; Neal JW
Oncologist; 2019 Jun; 24(6):836-843. PubMed ID: 30126856
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study.
Zhai X; Li W; Li J; Jia W; Jing W; Tian Y; Xu S; Li Y; Zhu H; Yu J
Radiat Oncol; 2021 Dec; 16(1):233. PubMed ID: 34865626
[TBL] [Abstract][Full Text] [Related]
5. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X
Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616
[TBL] [Abstract][Full Text] [Related]
6. Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Tozuka T; Noro R; Mizutani H; Kurimoto F; Hakozaki T; Hisakane K; Naito T; Takahashi S; Taniuchi N; Yajima C; Hosomi Y; Hirose T; Minegishi Y; Okano T; Kamio K; Yamaguchi T; Seike M;
Lung Cancer; 2024 May; 191():107540. PubMed ID: 38614069
[TBL] [Abstract][Full Text] [Related]
7. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
Magnuson WJ; Lester-Coll NH; Wu AJ; Yang TJ; Lockney NA; Gerber NK; Beal K; Amini A; Patil T; Kavanagh BD; Camidge DR; Braunstein SE; Boreta LC; Balasubramanian SK; Ahluwalia MS; Rana NG; Attia A; Gettinger SN; Contessa JN; Yu JB; Chiang VL
J Clin Oncol; 2017 Apr; 35(10):1070-1077. PubMed ID: 28113019
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of upfront craniocerebral radiotherapy and epidermal growth factor receptor-tyrosine kinase inhibitors in patients with epidermal growth factor receptor-positive non-small cell lung cancer with brain metastases.
Zhou J; Zhou Y; Sun Y; Xiao L; Lu H; Yin X; Fan K
Front Oncol; 2023; 13():1259880. PubMed ID: 38313214
[TBL] [Abstract][Full Text] [Related]
9. Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases.
Magnuson WJ; Yeung JT; Guillod PD; Gettinger SN; Yu JB; Chiang VL
Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):673-9. PubMed ID: 27034176
[TBL] [Abstract][Full Text] [Related]
10. Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases.
Miyawaki E; Kenmotsu H; Mori K; Harada H; Mitsuya K; Mamesaya N; Kawamura T; Kobayashi H; Nakashima K; Omori S; Wakuda K; Ono A; Naito T; Murakami H; Endo M; Nakasu Y; Gon Y; Takahashi T
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):604-613. PubMed ID: 30851347
[TBL] [Abstract][Full Text] [Related]
11. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
[TBL] [Abstract][Full Text] [Related]
12. The value of local consolidative therapy in Osimertinib-treated non-small cell lung cancer with oligo-residual disease.
Zeng Y; Ni J; Yu F; Zhou Y; Zhao Y; Li S; Guo T; Chu L; Yang X; Chu X; Cai X; Zhu Z
Radiat Oncol; 2020 Aug; 15(1):207. PubMed ID: 32854745
[TBL] [Abstract][Full Text] [Related]
13. Pattern of Recurrence Analysis in Metastatic EGFR-Mutant NSCLC Treated with Osimertinib: Implications for Consolidative Stereotactic Body Radiation Therapy.
Guo T; Ni J; Yang X; Li Y; Li Y; Zou L; Wang S; Liu Q; Chu L; Chu X; Li S; Ye L; Zhu Z
Int J Radiat Oncol Biol Phys; 2020 May; 107(1):62-71. PubMed ID: 31987959
[TBL] [Abstract][Full Text] [Related]
14. Real-world data on treatment outcomes in
Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
[TBL] [Abstract][Full Text] [Related]
15. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.
Byeon S; Ham JS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Med Oncol; 2016 Aug; 33(8):97. PubMed ID: 27447711
[TBL] [Abstract][Full Text] [Related]
17. Upfront Use of First-/Second-Generation EGFR-TKI Followed by Osimertinib Shows Better Prognosis than Upfront Osimertinib Therapy in Japanese Patients with Non-small-cell Lung Cancer with Exon 19 Deletion: A Single-Center Retrospective Study.
Hori T; Yamamoto K; Ito T; Ikushima S; Omura T; Yano I
Biol Pharm Bull; 2023; 46(6):788-795. PubMed ID: 37258143
[TBL] [Abstract][Full Text] [Related]
18. Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis.
Hyun DG; Choi CM; Lee DH; Kim SW; Yoon S; Kim WS; Ji W; Lee JC
PLoS One; 2020; 15(4):e0231546. PubMed ID: 32298306
[TBL] [Abstract][Full Text] [Related]
19. The optimal therapy strategy for epidermal growth factor receptor-mutated non-small cell lung cancer patients with brain metastasis: A real-world study from Taiwan.
Cheng WC; Shen YC; Chien CR; Liao WC; Chen CH; Hsia TC; Tu CY; Chen HJ
Thorac Cancer; 2022 May; 13(10):1505-1512. PubMed ID: 35394114
[TBL] [Abstract][Full Text] [Related]
20. Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors.
Lee JH; Chen HY; Hsu FM; Chen JS; Liao WY; Shih JY; Yu CJ; Chen KY; Tsai TH; Yang JC
Oncologist; 2019 Dec; 24(12):e1417-e1425. PubMed ID: 31127020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
